🚀 VC round data is live in beta, check it out!
Vivoryon Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Vivoryon Therapeutics and similar public comparables like Acrivon Therapeutics, Incannex, Vicapsys, Oncopeptides and more.
Vivoryon Therapeutics Overview
About Vivoryon Therapeutics
Vivoryon Therapeutics NV is a clinical-stage biopharmaceutical company focused on discovering, developing, and potentially commercializing small-molecule-based medicines that modulate the activity and stability of pathologically altered proteins. Vivoryon is currently focused on developing treatments for chronic kidney disease (CKD), and more precisely, is initially targeting stage 3b and worse diabetic kidney disease (DKD). Its product pipeline includes various drug candidates, including varoglutamstat (PQ912), VY2149, and NCE, as potential treatments for chronic kidney disease (CKD), and more precisely, are initially targeting stage 3b and worse diabetic kidney disease (DKD). The company is also pursuing antibody-based approaches for Alzheimer’s disease.
Founded
1997
HQ
Employees
15
Website
Sectors
Financials (LTM)
EV
$43M
Vivoryon Therapeutics Financials
Vivoryon Therapeutics reported last 12-month revenue of — and negative EBITDA of ($13M).
In the same LTM period, Vivoryon Therapeutics generated ($6K) in gross profit, ($13M) in EBITDA losses, and had net loss of ($13M).
Revenue (LTM)
Vivoryon Therapeutics P&L
In the most recent fiscal year, Vivoryon Therapeutics reported revenue of — and EBITDA of ($23M).
Vivoryon Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Gross Profit | ($6K) | XXX | — | XXX | XXX | XXX |
| EBITDA | ($13M) | XXX | ($23M) | XXX | XXX | XXX |
| Net Profit | ($13M) | XXX | ($23M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Vivoryon Therapeutics Stock Performance
Vivoryon Therapeutics has current market cap of $48M, and enterprise value of $43M.
Market Cap Evolution
Vivoryon Therapeutics' stock price is $1.63.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $43M | $48M | 0.4% | XXX | XXX | XXX | $-0.77 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVivoryon Therapeutics Valuation Multiples
Vivoryon Therapeutics trades at (3.2x) EV/EBITDA.
EV / Revenue (LTM)
Vivoryon Therapeutics Financial Valuation Multiples
As of March 25, 2026, Vivoryon Therapeutics has market cap of $48M and EV of $43M.
Equity research analysts estimate Vivoryon Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vivoryon Therapeutics has a P/E ratio of (3.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $48M | XXX | $48M | XXX | XXX | XXX |
| EV (current) | $43M | XXX | $43M | XXX | XXX | XXX |
| EV/EBITDA | (3.2x) | XXX | (1.9x) | XXX | XXX | XXX |
| EV/EBIT | (3.2x) | XXX | (1.8x) | XXX | XXX | XXX |
| EV/Gross Profit | (7363.3x) | XXX | — | XXX | XXX | XXX |
| P/E | (3.6x) | XXX | (2.1x) | XXX | XXX | XXX |
| EV/FCF | (3.1x) | XXX | (2.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Vivoryon Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Vivoryon Therapeutics Margins & Growth Rates
Vivoryon Therapeutics' revenue in the last fiscal year declined by (100%).
Vivoryon Therapeutics' revenue per employee in the last FY averaged $0.0M.
Vivoryon Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | (45%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Vivoryon Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Acrivon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Incannex | XXX | XXX | XXX | XXX | XXX | XXX |
| Vicapsys | XXX | XXX | XXX | XXX | XXX | XXX |
| Oncopeptides | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vivoryon Therapeutics M&A Activity
Vivoryon Therapeutics acquired XXX companies to date.
Last acquisition by Vivoryon Therapeutics was on XXXXXXXX, XXXXX. Vivoryon Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Vivoryon Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVivoryon Therapeutics Investment Activity
Vivoryon Therapeutics invested in XXX companies to date.
Vivoryon Therapeutics made its latest investment on XXXXXXXX, XXXXX. Vivoryon Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Vivoryon Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Vivoryon Therapeutics
| When was Vivoryon Therapeutics founded? | Vivoryon Therapeutics was founded in 1997. |
| Where is Vivoryon Therapeutics headquartered? | Vivoryon Therapeutics is headquartered in Germany. |
| How many employees does Vivoryon Therapeutics have? | As of today, Vivoryon Therapeutics has over 15 employees. |
| Who is the CEO of Vivoryon Therapeutics? | Vivoryon Therapeutics' CEO is Frank Weber. |
| Is Vivoryon Therapeutics publicly listed? | Yes, Vivoryon Therapeutics is a public company listed on Euronext Amsterdam. |
| What is the stock symbol of Vivoryon Therapeutics? | Vivoryon Therapeutics trades under VVY ticker. |
| When did Vivoryon Therapeutics go public? | Vivoryon Therapeutics went public in 2014. |
| Who are competitors of Vivoryon Therapeutics? | Vivoryon Therapeutics main competitors are Acrivon Therapeutics, Incannex, Vicapsys, Oncopeptides. |
| What is the current market cap of Vivoryon Therapeutics? | Vivoryon Therapeutics' current market cap is $48M. |
| Is Vivoryon Therapeutics profitable? | No, Vivoryon Therapeutics is not profitable. |
| What is the current EBITDA of Vivoryon Therapeutics? | Vivoryon Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Vivoryon Therapeutics? | Current EBITDA multiple of Vivoryon Therapeutics is (3.2x). |
| What is the current FCF of Vivoryon Therapeutics? | Vivoryon Therapeutics' last 12 months FCF is ($14M). |
| What is the current EV/FCF multiple of Vivoryon Therapeutics? | Current FCF multiple of Vivoryon Therapeutics is (3.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.